Skip to main content
    B

    Bio-Rad Laboratories Inc (BIO-B)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $389.98
    +0.00 (+0.00%)

    Market Cap: $10.49B

    Last updated: Nov 16, 2026 at 4:10 PM ET

    Bio-Rad Laboratories Inc (BIO-B) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Bio-Rad Laboratories reported EPS of $17.02. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    70%(21/30)
    Avg Surprise
    +24.74%
    Streak
    2 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$2.86
    Range$2.68 - $3.07
    4 analysts
    Revenue Consensus
    $695.54M
    Range$672.98M - $725.13M
    4 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS ConsensusN/A
    RangeN/A
    Revenue Consensus
    $611.30M
    Range$611.30M - $611.30M
    1 analysts

    Next Report

    Analysts' consensus for the quarter ending Dec 31, 2026 is 89.3% below the $26.65 reported for the quarter ended Dec 31, 2025.

    BIO-B's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    BIO-B Earnings Call

    The latest BIO-B earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 30 quarters below that had an estimate, BIO-B beat 21 and missed 9. Revenue for the quarter ended Sep 30, 2026 was $656.40M, up 0.5% from $653.00M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$17.02N/AN/AN/AN/AN/AN/AN/ANov 4, 2026$656.40M
    Jun 30, 2026$13.85N/AN/AN/AN/A+18.7%N/AN/AAug 4, 2026$651.00M
    Mar 31, 2026-$19.55N/AN/AN/AN/A-954.0%N/AN/AApr 30, 2026$592.10M
    Dec 31, 2025$26.65N/AN/AN/AN/AN/AN/AN/AFeb 12, 2026$693.20M
    Sep 30, 2025-$12.70N/AN/AN/AN/A-154.4%N/A0 up, 0 downOct 28, 2025$653.00M
    Jun 30, 2025$11.67N/AN/AN/AN/AN/AN/A0 up, 0 downJul 30, 2025$651.60M
    Mar 31, 2025$2.29N/AN/AN/AN/A-83.0%N/A0 up, 0 downMay 5, 2025$585.40M
    Dec 31, 2024-$25.57N/AN/AN/AN/A-924.7%N/A0 up, 0 downFeb 13, 2025$667.48M
    Sep 30, 2024$23.34N/AN/AN/AN/A+901.7%N/AN/AOct 30, 2024$649.73M
    Jun 30, 2024-$76.26N/AN/AN/AN/A-2642.1%N/AN/AAug 1, 2024$638.48M
    Mar 31, 2024$13.45$2.99N/A+349.94%Beat+302.8%N/AN/AMay 7, 2024$610.82M
    Dec 31, 2023$3.10$2.84N/A+9.15%Beat-6.3%N/AN/AFeb 29, 2024$681.18M
    Sep 30, 2023$2.33$2.76N/A-15.58%Miss-10.4%N/AN/AOct 27, 2023$632.12M
    Jun 30, 2023$3.00$2.64N/A+13.64%Beat-11.2%N/AN/AAug 4, 2023$681.11M
    Mar 31, 2023$3.34$3.63N/A-7.99%Miss-32.4%N/AN/AMay 5, 2023$676.84M
    Dec 31, 2022$3.31$3.48N/A-4.89%Miss+3.1%N/AN/AFeb 17, 2023$730.29M
    Sep 30, 2022$2.60$2.70N/A-3.70%Miss-29.9%N/AN/AOct 28, 2022$680.80M
    Jun 30, 2022$3.38$2.72N/A+24.26%Beat-4.5%N/AN/AJul 29, 2022$691.10M
    Mar 31, 2022$4.94$3.34N/A+47.90%Beat-5.2%N/AN/AApr 29, 2022$700.06M
    Dec 31, 2021$3.21$2.82N/A+13.83%Beat-20.0%N/AN/AFeb 11, 2022$732.77M
    Sep 30, 2021$3.71$2.31N/A+60.61%Beat+23.7%N/AN/AOct 29, 2021$747.05M
    Jun 30, 2021$3.54$2.55N/A+38.82%Beat+119.9%N/AN/AJul 30, 2021$715.93M
    Mar 31, 2021$5.21$2.96N/A+76.01%Beat+172.8%N/AN/AApr 30, 2021$726.80M
    Dec 31, 2020$4.01$3.24N/A+23.77%Beat+72.8%N/AN/AFeb 12, 2021$789.84M
    Sep 30, 2020$3.00$1.80N/A+66.67%Beat+86.3%N/AN/AOct 30, 2020$647.26M
    Jun 30, 2020$1.61$1.22N/A+31.97%Beat+2.5%N/AN/AJul 30, 2020$536.88M
    Mar 31, 2020$1.91$1.57N/A+21.66%Beat+15.8%N/AN/AMay 6, 2020$571.64M
    Dec 31, 2019$2.32$2.44N/A-4.92%Miss+8.9%N/AN/AFeb 13, 2020$624.43M
    Sep 30, 2019$1.61$1.41N/A+14.18%Beat+76.9%N/AN/AOct 31, 2019$560.63M
    Jun 30, 2019$1.57$1.32N/A+18.94%Beat-4.3%N/AN/AAug 1, 2019$572.62M
    Mar 31, 2019$1.65$1.14N/A+44.74%Beat+41.0%N/AN/AMay 8, 2019$553.98M
    Dec 31, 2018$2.13$1.70N/A+25.29%Beat+317.6%N/AN/AFeb 28, 2019$616.85M
    Sep 30, 2018$0.91$1.18N/A-22.88%Miss0.0%N/AN/ANov 1, 2018$545.14M
    Jun 30, 2018$1.64$1.27N/A+29.13%Beat+864.7%N/AN/AAug 7, 2018$575.91M
    Mar 31, 2018$1.17$1.07N/A+9.35%Beat+178.6%N/AN/AApr 13, 2018$551.52M
    Dec 31, 2017$0.51$1.26N/A-59.52%MissN/AN/AN/AFeb 27, 2018$620.43M
    Sep 30, 2017$0.91$0.38N/A+139.47%Beat+46.8%N/AN/ANov 2, 2017$535.00M
    Jun 30, 2017$0.17$0.56N/A-69.64%Miss-72.1%N/AN/AAug 3, 2017$504.67M
    Mar 31, 2017$0.42$0.30N/A+40.00%Beat0.0%N/AN/AMay 4, 2017$500.05M
    Dec 31, 2016-$0.70$1.03N/A-167.96%Miss-141.7%N/AN/AFeb 23, 2017$571.45M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $27.92, a profit after a loss of $65.04 per share the year before. It was $0.95 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$27.92N/A
    Dec 31, 2024-$65.04-652.6%
    Dec 31, 2023$11.77-17.3%
    Dec 31, 2022$14.23-9.2%
    Dec 31, 2021$15.67+48.8%
    Dec 31, 2020$10.53+47.3%
    Dec 31, 2019$7.15+22.2%
    Dec 31, 2018$5.85+191.0%
    Dec 31, 2017$2.01+111.6%
    Dec 31, 2016$0.95N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,5048
    2026Q2Jun 30, 20266,0479
    2026Q1Mar 31, 20265,23210
    2025Q4Dec 31, 20254,1697
    2025Q3Sep 30, 20252,6885
    2025Q2Jun 30, 20255,74811
    2025Q1Mar 31, 20254,3489
    2024Q4Dec 31, 20246,29311

    2026Q3 Earnings Call

    Opening remarks

    Ruben Argueta Head of Investor Relations Thank you, operator. Good afternoon, everyone, and thank you for joining us. Today, we will review the financial results for the third quarter ended September 30, 2026, and provide an update on key business trends for Bio-Rad. With me on the call today are Norman Schwartz, our Chief Executive Officer; Jon DiVincenzo, President and Chief Operating Officer; and Roop Lakkaraju, Executive Vice President and Chief Financial Officer. Before we begin our review, I would like to remind everyone that we will be making forward-looking statements about management's goals, plans and expectations; our future financial performance and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Our actual results may differ materially from these plans, goals and expectations. You should not place undue reliance on these forward-looking statements, and I encourage you to review our filings with the SEC, where we discuss in detail the risk factors in our business. The company does not intend to update any forward-looking statements made during the call today. Finally, our remarks today will include references to non-GAAP financials, including net income and diluted earnings per share, which are financial measures that are not defined under generally accepted accounting principles. In addition to excluding certain atypical and nonrecurring items, our non-GAAP financial measures exclude changes in the equity value of our stake in Sartorius AG in order to provide investors with a better understanding of Bio-Rad's underlying operational performance. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release. We have also posted a supplemental earnings presentation in the Investor Relations section of our website for your reference. With that, I will now turn the call over to our Chief Operating Officer, Jon DiVincenzo.

    Jonathan DiVincenzo President and Chief Operating Officer Thanks, Ruben. Good afternoon, everyone, and thank you for joining us. The third quarter represented another step forward in our efforts to improve Bio-Rad's operating and financial performance. Total company revenue in the third quarter was approximately $656 million, an increase of 0.5% on a reported basis and 0.7% on a currency-neutral basis compared with the prior year. This was our first quarter of currency-neutral growth this year. Gross margin expanded to 54.5% on a non-GAAP basis. While the pace of revenue growth remains modest, we are encouraged by the progress across several areas of the business. Clinical Diagnostics returned to growth, supported by Quality Systems and Diabetes products. In Life Science, excluding Process Chromatography, revenue increased 2.5% year-over-year. This represents the third consecutive quarter of sequential improvement in the growth rate. It was driven by our Genomics portfolio, including our Droplet Digital PCR business, led by the QX700 portfolio.

    Frequently Asked Questions About BIO-B

    What EPS do analysts expect from BIO-B next quarter?

    The consensus EPS estimate for Bio-Rad Laboratories for the quarter ending Dec 31, 2026 is $2.86 from 4 analysts, with estimates from $2.68 to $3.07.

    How often does BIO-B beat earnings estimates?

    Bio-Rad Laboratories beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of +45.61%.